Eligibility
Applicant must be a highly qualified investigator holding an independent faulty-level appointment who is conducting original, independently applied research, often involving early-stage clinical trials advancing the prevention, diagnosis or treatment of hematologic malignancies. It is expected applicant will have research funding in place from another source or agency.